Aktiesnakken — Marts 2010
-
vent lidt - det er vist en reach-around...
-
jeg har slået mig alvorligt på kaffelatte i løbet af dagen. MÅske er det et udslag af kedsomhed og understimulering...
-
nu
-
-
masser af likvider
-
1281 mio likvider ultimo 2009
-
underskud i low range
-
burn på 600 mio ex arzerra royalties
-
burn liggger lige omkring 2 år....det er godkendt
-
der budgetteres med salg af fabrikken i 2010
-
værdisat til 750 mio
-
men det er ex arzerra
-
Genmab er
endvidere berettiget til at modtage trinvist stigende tocifrede royaltyprocenter fra
det globale salg af ofatumumab.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind